Neurodegenerative Disorders Parkinson Drug Alzheimer Drug Biomarkers Insight 2028

• Global Alzheimer’s Disease Antibodies Market Opportunity: > USD 5 Billion
• Alzheimer’s Disease Clinical Trials Insight: > 200 Drugs In Trials
• Alzheimer’s Disease Biomarkers Sourced During Clinical Trials
• Alzheimer’s Disease Insight By Classification
• Insight On Biomarkers Sourced From Trials By Drugs & Indication
• Biomarker Name & Function Insight By Drug
• Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

Download Report Sample:

http://biomarkersinsights.com/alzheimers-disease-biomarkers-and-clinical-trials-insight-2028

Neurodegenerative disorders are usually characterized by accumulation of abnormal protein aggregation that leads to inflammation as well as oxidative stress in the central nervous system (CNS). Parkinson’s disease (PD) and Alzheimer’s disease (AD) are the most common disorders of nervous system caused by environmental and genetic influences. It has been observed that various types of biological mechanisms are associated with neurodegenerative disorders such as oxidative stress, aggregates of proteins in neurons, depletion or in sufficient synthesis of neurotransmitters, degradation of neurotransmitters in the synaptic cleft due to the higher activity of enzymes, abnormal ubiquitination, and damage of blood brain barrier.

Parkinson’s disease (PD) is one of the common chronic degenerative conditions of the nervous system. There is currently no cure for PD, but a number of drugs offer benefits in terms of controlling the motor symptoms. . Commonly used drugs for PD include those based on exogenous administration of compounds with dopaminergic activity (e.g. levodopa, dopamine agonists), and those that inhibit the metabolism of endogenous dopamine (e.g. COMT, MAO-B inhibitors). While these drugs significantly enhance the motor functions, they are associated with problematic side effects. This has surged the demand of more targeted therapeutics for the management of disease. To date, about 500 clinical trials are ongoing in global Parkinson drug market.

In contrast, Alzheimer disease is the most common form of dementia which presents progressive memory decline initially. It is accompanied by other cognitive dysfunctions, such as visuospatial abnormalities, navigation difficulties, executive problems, and language disturbance. These cognitive impairments further affect daily life activities, and many behavioral psychological symptoms of dementia (BPSD) usually occur during the disease course. Presently, the management of Alzheimer disease consists mainly of symptomatic treatments of which there are six approved medications belonging to drug class acetylcholinesterases, NMDA, combination therapy, and Aβ A4 protein inhibitor. Recently in 2021, US FDA has granted approval to Aduhelm as the first Alzheimer’s disease treatment to address the pathology of disease.

Some of the key market players in the global neurodegenerative disease market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline. Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non-government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. Luye Pharma and Towa Pharmaceutical announced a strategic agreement in February 2021 to develop and market Rivastigmine Multi-Day Transdermal Patch in Japan. Luye Pharma created the Rivastigmine Multi-Day Transdermal Patch, which treats Alzheimer’s disease.

As per our report findings, the global Parkinson drug market is expected to surpass US$ 8 Billion by 2028 whereas global Alzheimer drug market is expected to surpass US$ 5 Billion by 2028. Due to patent protection loss, new players are expected to enter the neurodegenerative disease market during the forecast years. In the Alzheimer’s market, drugs like GABA receptor modulators, anti-amyloid protein agents and nicotinic and cholinergic receptor agonists are expected to influence the neurodegenerative disease market growth. However, the Parkinson’s disease market will be driven due to the launch of drugs like dopamine receptor agonists and reuptake inhibitors, glutamate receptor modulators, and adrenergic and adenosine antagonists.

Our report provides in-depth analysis on the currently available biomarker across various stages of clinical trial. The study also provides insights into commercially available drugs for Parkinson disease and Alzheimer disease, and major drugs in research and development. This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges that will determine the market’s future growth.

Contact:
Preeti Dureja
Research Partner
Biomarkers Insights
sample@biomarkersinsights.com
www.biomarkersinsights.com